"INDICATORS"? What "INDICATORS" would those be?
Their 9 straight quarters of double-digit YOY revenue increases? Their $18.3 million in 2016 revenues? Their plan (in progress even now) to uplist to OTCQB? The fact that they're on-track to hit $22 million in revenues this year? Please, INDICATE away...
MIDAM's sell-off is over, and share price has remained flat since then. With April numbers, we'll see a price increase, and once RXMD uplists to OTCQB, we'll be hitting the radar of a whole new pool of investors. With no more artificial downward pressures, share prices will never be this low again. (In fact, if MIDAM eventually has to repurchase their shares, we may see an even larger price jump.)
RXMD is headed for record new share price heights this year. Buy now, or cry later.
News 
Market Data 
Discover 
